Remepy Names Eran Harary Chief Medical Officer

Sep 16, 2026
Eran Harary will lead clinical strategy, trial execution, and regulatory engagement as Remepy prepares its Parkinson's treatment for Phase III development.

Remepy has appointed Eran Harary, MD, as chief medical officer, effective October 1, 2026, the company said in a press release. He will oversee clinical strategy, trial execution, and medical and regulatory engagement across the company's Hybrid Drug pipeline.

Harary joins from Teva Pharmaceuticals, where his roles included global head of specialty research and development and global head of early clinical development. He led UZEDY through approval and contributed to the development of AUSTEDO, with experience across neuroscience, immunology, neurology, psychiatry, and long acting injectable treatments.

Remepy combines prescription medicines with personalized therapeutic apps that use AI to provide physical, cognitive, and behavioral interventions. Its lead program, Hybridopa for Parkinson's disease, has reported Phase IIa results and is expected to begin global Phase III development in the fourth quarter of 2026.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.